A new clinical trial, co-led by endocrinologist and diabetes expert John Buse, MD, PhD, and interventional cardiologist Matthew Cavender, MD, MPH, at the UNC School of Medicine has shown that the oral form of semaglutide can significantly reduce cardiovascular events in people with type 2 diabetes and atherosclerotic cardiovascular disease, and/or chronic kidney disease
Her story is a testament to the power of a truly personalized, medically supervised approach to weight loss
BPC-157, short for Body Protection Compound 157, is a synthetic peptide made up of 15 amino acids
Discuss your specific supplement plan with your PlexusDx provider during your initial consultation
Clinical studies indicate an average 15% reduction in body weight over 68 weeks, making Wegovy a proven choice for those seeking significant weight loss
After four weeks at 0.25 mg, most patients move to 0.5 mg weekly